The new ICH E6(R3) GCP guideline, impacting clinical studies starting 23 July 2025, introduces significantly more detailed requirements around the integrity and governance of data assets and trial records, including biospecimens, their derivatives, and all associated clinical and assay data generated during trials. To help precision medicine teams ensure they meet these new requirements, we have developed this compliance checklist.
This month, we released version 11.0.0 of QuartzBio’s Precision Medicine AI Agent Platform, featuring enhancements to our Sample Intelligence Solution, our Biomarker Intelligence Solution, and performance improvements to our data management layer.
I just read Microsoft’s latest Work Trend Index report, “The Year the Frontier Firm Is Born,” and it resonates deeply with the challenges and opportunities we’re seeing in precision medicine R&D. Read about QuartzBio’s approach and find links to additional resources on deploying precision medicine AI agents.
Watch Tobi Guennel, Ph.D., QuartzBio’s Co-founder and Chief Technology Officer, demonstrate how a network of domain-specific AI agents, orchestrated by our first-in-class Virtual Assistant, empowers informatics, translational, and IT teams to conversationally explore and visualize clinical, sample, and biomarker data. The QuartzBio AI Agent network can perform tasks semi-autonomously based on expected events and observed data trends.
Join this webinar to learn how to use QuartzBio’s AI Agent Platform. You can ask questions, get answers, and gain insights at the speed of decision-making. Domain-specific AI agents, orchestrated by our Virtual Assistant, enable operations, translational, and informatics teams to conversationally interact with a connected ecosystem of biomarker, sample, and clinical data.
Watch the full episode: Tobi Guennel, PhD, SVP of Product Innovation at QuartzBio, joins AI expert Srivatsan Nagaraja to discuss his insights on integrating AI into the precision medicine value chain in an episode of the Life Sciences D’n’A Podcast. Tune in to learn about: Can’t see the video? Accept cookies to watch: Contact us […]
The promise of precision medicine starts with the sample data value chain. This value chain was the focus of an exciting session at the 2025 SCOPE Summit for Clinical Operations Executives. QuartzBio’s Tobi Guennel, PhD, inspired lively discussion in his presentation, “From Site to Result: Real-Time Sample Intelligence Unlocked with GenAI.”He explored the opportunities for technology to empower the people and processes across the entire sample data value chain.
This month, we released version 10.0.0 of the QuartzBio Platform, delivering enhancements to our solutions for biomarker and sample intelligence, as well as the underlying Enterprise Data Platform, which supports data management activities.
Interoperability in R&D: What does it mean? In modern drug development, connectedness is crucial for success, especially in remote and decentralized teams. This connectedness involves linking people and information to extract shared insights from data and make faster decisions. In practice, this means ensuring interoperability of data, technology, systems, and ecosystems through a scalable, modular […]
QuartzBio is the only company purpose-built to deliver end-to-end Sample and Biomarker Intelligence for clinical-stage biopharma teams. Powered by a network of domain-specific AI agents, our solutions transform fragmented data into actionable intelligence, enabling conversational insights into your unified ecosystem of sample, clinical, and biomarker data.
QUARTZBIO® is a registered trademark of Precision Regulatory and Translational Sciences, Inc., dba QuartzBio, in the United States and/or other jurisdictions. All rights reserved.
© 2026 QuartzBio.
All rights reserved.
Privacy Notice
Ethics & Third-Party Notice
